Compare fund portfolios
See how two funds' portfolios overlap. Enter two tickers:
LHCFX vs GGHCX
Shared holdings
32
LHCFX covered by GGHCX
39.95%
GGHCX covered by LHCFX
39.95%
Coverage = share of one portfolio's weight reproduced by the other (overlapping positions, min weight). Top 50 positions per side shown; = held by both — hover a shared position to highlight it in both columns.
LHCFX (April 30, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 8.73% | |
| ASTRAZENECA PLC | 4.64% | |
| GILEAD SCIENCES INC | 4.17% | |
| JOHNSON&JOHNSON | 3.13% | |
| NEKTAR THERAPEUTICS | 3.11% | |
| NATERA INC | 2.86% | |
| TARSUS PHARMACEUTICALS INC | 2.78% | |
| GUARDANT HEALTH INC | 2.58% | |
| ARGENX SE | 2.51% | |
| Novartis AG (Registered) | 2.42% | |
| CVS HEALTH CORP | 2.33% | |
| MADRIGAL PHARMACEUTICALS INC | 2.18% | |
| INTUITIVE SURGICAL INC | 2.17% | |
| COGENT BIOSCIENCES INC | 2.15% | |
| GALDERMA GROUP A | 2.07% | |
| UNITEDHEALTH GRP | 2.06% | |
| CELCUITY INC | 1.97% | |
| BRIDGEBIO PHARMA INC | 1.95% | |
| CENCORA INC | 1.95% | |
| Ascendis Pharma A/S | 1.93% | |
| Abivax SA SPONSORED ADS | 1.83% | |
| EDWARDS LIFESCIENCES CORP | 1.79% | |
| FIXED INC CLEARING CORP.REPO | 1.75% | |
| MIRUM PHARMACEUTICALS INC | 1.72% | |
| UCB SA | 1.71% | |
| MONEY MARKET FUND | 1.69% | |
| DIANTHUS THERAPEUTICS INC | 1.67% | |
| UNITED THERAPEUTICS CORP DEL | 1.61% | |
| VERTEX PHARMACEUTICALS INC | 1.60% | |
| THERMO FISHER SCIENTIFIC INC | 1.45% | |
| REVOLUTION MEDICINES INC | 1.33% | |
| TEVA PHARMACEUTICAL IND ADR | 1.25% | |
| ADAPTIVE BIOTECHNOLOGIES CORP | 1.15% | |
| PTC THERAPEUTICS INC | 1.10% | |
| INSMED INC | 1.04% | |
| MINERALYS THERAPEUTICS INC | 1.03% | |
| OTSUKA HOLDINGS | 1.02% | |
| CG ONCOLOGY INC | 0.98% | |
| BEONE MEDICINE-H | 0.93% | |
| RHYTHM PHARMACEUTICALS INC | 0.92% | |
| GLAUKOS CORP | 0.91% | |
| ARROWHEAD PHARMACEUTICALS INC | 0.85% | |
| 10X GENOMICS INC | 0.85% | |
| HEARTFLOW INC | 0.85% | |
| ENCOMPASS HEALTH CORP | 0.82% | |
| GENEDX HOLDINGS CORP-A | 0.79% | |
| TRANSMEDICS GROUP INC | 0.79% | |
| DBV TECHNOLOGIES SA SPON ADR | 0.75% | |
| STRYKER CORP | 0.71% | |
| PROTAGONIST THERAPEUTICS INC | 0.69% |
GGHCX (Jan. 31, 2026)
| Security | Weight | |
|---|---|---|
| LILLY ELI and CO | 9.23% | |
| BOSTON SCIENTIFIC CORP | 4.93% | |
| ABBVIE INC | 4.86% | |
| CENCORA INC | 4.58% | |
| GILEAD SCIENCES INC | 3.76% | |
| ASTRAZENECA PLC SPONS ADR | 3.68% | |
| ARGENX SE SPONSORED ADR | 3.50% | |
| JOHNSON&JOHNSON | 3.30% | |
| MCKESSON CORP | 3.11% | |
| Invesco Private Prime Fund | 2.43% | |
| THERMO FISHER SCIENTIFIC INC | 2.26% | |
| HCA HEALTHCARE INC | 1.90% | |
| INTUITIVE SURGICAL INC | 1.80% | |
| Invesco Treasury Portfolio, Institutional Class | 1.78% | |
| WELLTOWER INC | 1.78% | |
| GUARDANT HEALTH INC | 1.70% | |
| Ascendis Pharma A/S | 1.68% | |
| NATERA INC | 1.56% | |
| IDEXX LABS INC | 1.54% | |
| BRIGHTSPRING HEALTH SERVICES INC | 1.49% | |
| INSMED INC | 1.49% | |
| ROYALTY PHARMA-A | 1.44% | |
| UCB SA | 1.40% | |
| UNITEDHEALTH GRP | 1.34% | |
| BRIDGEBIO PHARMA INC | 1.31% | |
| AXSOME THERAPEUTICS INC | 1.27% | |
| TENET HEALTHCARE CORP | 1.19% | |
| VERTEX PHARMACEUTICALS INC | 1.19% | |
| ALNYLAM PHARMACEUTICALS INC | 1.12% | |
| ENCOMPASS HEALTH CORP | 1.07% | |
| INSULET CORP | 1.06% | |
| REGENERON PHARMACEUTICALS INC | 1.06% | |
| METTLER-TOLEDO INTL INC | 1.05% | |
| STRYKER CORP | 1.01% | |
| UNITED THERAPEUTICS CORP DEL | 0.99% | |
| SANDOZ GRP. AG | 0.94% | |
| Invesco Private Government Fund | 0.93% | |
| Invesco Government & Agency Portfolio, Institutional Class | 0.93% | |
| AGILENT TECHNOLOGIES INC | 0.92% | |
| EDWARDS LIFESCIENCES CORP | 0.90% | |
| HALOZYME THERAPEUTICS INC | 0.87% | |
| MADRIGAL PHARMACEUTICALS INC | 0.81% | |
| LONZA GROUP -REG | 0.80% | |
| CARDINAL HEALTH INC | 0.75% | |
| GALDERMA GRP. AG | 0.73% | |
| CVS HEALTH CORP | 0.70% | |
| IONIS PHARMACEUTICALS INC | 0.70% | |
| PROTAGONIST THERAPEUTICS INC | 0.67% | |
| STERIS PLC | 0.61% | |
| LIGAND PHARMACEUTICALS | 0.60% |
Machine-readable: JSON · Markdown. Programmatic access via the agent surface.